CSL’s Acquisition of Vifor Pharma Hits Antitrust Snags

The multinational biotech CSL’s planned purchase of Vifor Pharma has been put on pause due to antitrust concerns. The $11.7 billion deal was set to close in June of this year, but CSL reported yesterday, May 11^th, 2022, that the regulatory approval process with several agencies will take longer than initially projected.

According to Nicole DeFeudis of Endpoints News, “Vifor noted that delays are “not unusual.” However, the FTC and its peers in Canada, Europe and the UK established a working group earlier this year to rethink the way they review pharma mergers — and some fear that increased scrutiny could lead to more delays.”

To read more, click here.

(Source: Endpoints News, May 12^th, 2022)